ConvergentRx
convergentrx.com
Biotechnology
Professional Services
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPC
Neil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.
Read more
Report
After Pluvicto: Alpha Radiopharma and Prostate Cancer
The post After Pluvicto: Alpha Radiopharma and Prostate Cancer appeared first on Convergent Therapeutics.
Read more
Report
Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The post Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC) appeared fi
Read more
Report
Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026
The post Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026 appeared first on Convergent Therapeutics.
Read more
Report
What Comes After Pluvicto? A New and Distinct Prostate Cancer Patient Subpopulation Is Taking Shape
The post What Comes After Pluvicto? A New and Distinct Prostate Cancer Patient Subpopulation Is Taking Shape appeared first on Convergent Therapeutics.
Read more
Report
What Comes After Pluvicto? A New and Distinct Prostate Cancer Patient Subpopulation Is Taking Shape
The success of Pluvicto has created a new challenge in prostate cancer, one the field has not yet fully named or defined.
Read more
Report
Convergent Therapeutics Announces Two Clinical Trial Updates on CONV01-α at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025
/PRNewswire/ -- Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the...
Read more
Report
Convergent Therapeutics Appoints Barbara Duncan to Board of Directors
/PRNewswire/ -- Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for...
Read more
Report
Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen
/PRNewswire/ -- Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for...
Read more
Report
Convergent Therapeutics Appoints Scott Myers as Chairman of its Board of Directors
/PRNewswire/ -- Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for...
Read more
Report
Show more news